These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31809194)

  • 1. A Type IV-A CRISPR-Cas System in
    Crowley VM; Catching A; Taylor HN; Borges AL; Metcalf J; Bondy-Denomy J; Jackson RN
    CRISPR J; 2019 Dec; 2(6):434-440. PubMed ID: 31809194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria.
    Hidalgo-Cantabrana C; Goh YJ; Barrangou R
    J Mol Biol; 2019 Jan; 431(1):21-33. PubMed ID: 30261168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SnapShot: CRISPR-RNA-guided adaptive immune systems.
    Carter J; Wiedenheft B
    Cell; 2015 Sep; 163(1):260-260.e1. PubMed ID: 26406380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unravelling the structural and mechanistic basis of CRISPR-Cas systems.
    van der Oost J; Westra ER; Jackson RN; Wiedenheft B
    Nat Rev Microbiol; 2014 Jul; 12(7):479-92. PubMed ID: 24909109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Requirements for Pseudomonas aeruginosa Type I-F CRISPR-Cas Adaptation Determined Using a Biofilm Enrichment Assay.
    Heussler GE; Miller JL; Price CE; Collins AJ; O'Toole GA
    J Bacteriol; 2016 Nov; 198(22):3080-3090. PubMed ID: 27573013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type IV CRISPR RNA processing and effector complex formation in Aromatoleum aromaticum.
    Özcan A; Pausch P; Linden A; Wulf A; Schühle K; Heider J; Urlaub H; Heimerl T; Bange G; Randau L
    Nat Microbiol; 2019 Jan; 4(1):89-96. PubMed ID: 30397343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of direct repeats and spacers of CRISPR/Cas systems type I-F in Brazilian clinical strains of Pseudomonas aeruginosa.
    Luz ACO; da Silva JMA; Rezende AM; de Barros MPS; Leal-Balbino TC
    Mol Genet Genomics; 2019 Oct; 294(5):1095-1105. PubMed ID: 31098740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unity among the diverse RNA-guided CRISPR-Cas interference mechanisms.
    Ganguly C; Rostami S; Long K; Aribam SD; Rajan R
    J Biol Chem; 2024 Jun; 300(6):107295. PubMed ID: 38641067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type IV CRISPR-Cas systems are highly diverse and involved in competition between plasmids.
    Pinilla-Redondo R; Mayo-Muñoz D; Russel J; Garrett RA; Randau L; Sørensen SJ; Shah SA
    Nucleic Acids Res; 2020 Feb; 48(4):2000-2012. PubMed ID: 31879772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to study CRISPR RNA biogenesis and the key players involved.
    Behler J; Hess WR
    Methods; 2020 Feb; 172():12-26. PubMed ID: 31325492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An active immune defense with a minimal CRISPR (clustered regularly interspaced short palindromic repeats) RNA and without the Cas6 protein.
    Maier LK; Stachler AE; Saunders SJ; Backofen R; Marchfelder A
    J Biol Chem; 2015 Feb; 290(7):4192-201. PubMed ID: 25512373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quorum sensing controls the Pseudomonas aeruginosa CRISPR-Cas adaptive immune system.
    Høyland-Kroghsbo NM; Paczkowski J; Mukherjee S; Broniewski J; Westra E; Bondy-Denomy J; Bassler BL
    Proc Natl Acad Sci U S A; 2017 Jan; 114(1):131-135. PubMed ID: 27849583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
    O'Connell MR
    J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
    Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type III CRISPR-Cas System: Introduction And Its Application for Genetic Manipulations.
    Liu T; Pan S; Li Y; Peng N; She Q
    Curr Issues Mol Biol; 2018; 26():1-14. PubMed ID: 28879852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA Guide Complementarity Prevents Self-Targeting in Type VI CRISPR Systems.
    Meeske AJ; Marraffini LA
    Mol Cell; 2018 Sep; 71(5):791-801.e3. PubMed ID: 30122537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas systems restrict horizontal gene transfer in Pseudomonas aeruginosa.
    Wheatley RM; MacLean RC
    ISME J; 2021 May; 15(5):1420-1433. PubMed ID: 33349652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Throughput Characterization of Cascade type I-E CRISPR Guide Efficacy Reveals Unexpected PAM Diversity and Target Sequence Preferences.
    Fu BX; Wainberg M; Kundaje A; Fire AZ
    Genetics; 2017 Aug; 206(4):1727-1738. PubMed ID: 28634160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three New Cs for CRISPR: Collateral, Communicate, Cooperate.
    Varble A; Marraffini LA
    Trends Genet; 2019 Jun; 35(6):446-456. PubMed ID: 31036344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR control of virulence in Pseudomonas aeruginosa.
    Wiedenheft B; Bondy-Denomy J
    Cell Res; 2017 Feb; 27(2):163-164. PubMed ID: 28084330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.